[The place of conservative surgery in the complex oncologic treatment of XXXX ].

@entity1 @entity0
For a long time, breast-conserving surgery has been a subject of great interest and debate. Many researchers have tried to find strict criteria in selecting the @entity1 who can benefit from such a treatment but this remains a goal to achieve in the future. In our surgical department, from 1984 to 2000, 1152 @entity1 were diagnosed with @entity0 . 741 @entity1 (64.1%) had @entity0 and 411 @entity1 (35.6%) were diagnosed in I and II stages. From the @entity1 with early @entity0 only 57 (14.1%) had benefited of conservative surgery combined with adjuvant radiotherapy and chemotherapy. All @entity1 received hormonotherapy. The surgical treatment consisted in a broad sectorectomy and axillary lymphadenectomy in all cases. We present the criteria for selecting @entity1 in our study. The @entity1 were followed for 2-5 years, with a mean period of 48 months and there were no significant differences between the trial with mamectomy and that with conservative surgery. There is presented a brief review of the literature in this field. Our conclusion is that the conservative surgery for @entity0 is a good method, which can be applied for selected @entity1 and with a good follow-up.
